GeneTex
  • Country / Location Selection

United States (US)

SARS-CoV-2-directed T cell Response in Convalescent and Vaccinated Individuals

08-Dec-2021

 

Understanding both the humoral (neutralizing antibodies) and cellular (T cell) immune response to SARS-CoV-2 infection or vaccination is essential for managing the COVID-19 pandemic. The widely reported phenomenon that humoral immunity wanes following both convalescence and vaccination has underscored the importance of assessing T cell-mediated protection against SARS-CoV-2. A concise yet detailed review by Bertoletti et al. analyzes the present data related to characterization of SARS-CoV-2-specific T cells and both their protective and pathological actions (1). The authors also survey the literature related to memory T cells induced by either natural infection or vaccination. In a second perspective, an original study by Jordan et al. reports that T cells generated by SARS-CoV-2 infection or vaccination demonstrate protective immunity against at least two VOCs (i.e., Alpha and Delta), offering encouraging insight that this may extend to other VOCs (2).

GeneTex has developed a comprehensive catalog of reagents for SARS-CoV-2/COVID-19 research, including antibodies that may detect the Omicron VOC based on immunogen sequence analysis. Please see the images below identifying several of these products and click here for more information.

 

GeneTex’s SARS-CoV-2 Antibodies Predicted to Detect the Omicron Variant

Spike RBD antibody [HL257] (GTX635692)

Spike RBD antibody [HL257] (GTX635692)

Spike S1 antibody [HL1] (GTX635656)

Spike S1 antibody [HL1] (GTX635656)

Spike S2 antibody [HL237] (GTX635693)

Spike S2 antibody [HL237] (GTX635693)

Spike antibody [1A9] (GTX632604)

Spike antibody [1A9] (GTX632604)

 

References:

  1. Cell Mol Immunol. 2021 Oct;18(10):2307-2312.
  2. Cell Mol Immunol. 2021 Nov;18(11):2554-2556.